{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:46:49Z","timestamp":1775749609640,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The efficacy of olanzapine as an antiemetic agent in cancer chemotherapy has been demonstrated. However, few high-quality reports are available on the evaluation of olanzapine\u2019s efficacy and safety at a low dose of 5\u2009mg among patients treated with carboplatin regimens. Therefore, in this study, we investigated the efficacy and safety of 5\u2009mg olanzapine for managing nausea and vomiting in cancer patients receiving carboplatin regimens and identified patient-related risk factors for carboplatin regimen-induced nausea and vomiting treated with 5\u2009mg olanzapine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were pooled for 140 patients from three multicenter, prospective, single-arm, open-label phase II studies evaluating the efficacy and safety of olanzapine for managing nausea and vomiting induced by carboplatin-based chemotherapy. Multivariable logistic regression analyses were performed to determine the patient-related risk factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Regarding the endpoints of carboplatin regimen-induced nausea and vomiting control, the complete response, complete control, and total control rates during the overall study period were 87.9, 86.4, and 72.9%, respectively. No treatment-related adverse events of grade 3 or higher were observed. The multivariable logistic regression models revealed that only younger age was significantly associated with an increased risk of non-total control. Surprisingly, there was no significant difference in CINV control between the patients treated with or without neurokinin-1 receptor antagonist.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The findings suggest that antiemetic regimens containing low-dose (5\u2009mg) olanzapine could be effective and safe for patients receiving carboplatin-based chemotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-021-08572-3","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T22:02:32Z","timestamp":1626732152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of 5\u2009mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials"],"prefix":"10.1186","volume":"21","author":[{"given":"Senri","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Uozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiyoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Karayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoh","family":"Hayasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiemi","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichirou","family":"Morishige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"issue":"1","key":"8572_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10549-013-2727-3","volume":"142","author":"I Kuchuk","year":"2013","unstructured":"Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S, et al. Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat. 2013;142(1):101\u20137. https:\/\/doi.org\/10.1007\/s10549-013-2727-3.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"8572_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","volume":"13","author":"CC Sun","year":"2005","unstructured":"Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005;13(4):219\u201327. https:\/\/doi.org\/10.1007\/s00520-004-0710-6.","journal-title":"Support Care Cancer"},{"issue":"12","key":"8572_CR3","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1007\/s00520-012-1448-1","volume":"20","author":"P Fern\u00e1ndez-Ortega","year":"2012","unstructured":"Fern\u00e1ndez-Ortega P, Caloto MT, Chirveches E, Marquilles R, Francisco JS, Quesada A, et al. Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life. Support Care Cancer. 2012;20(12):3141\u20138. https:\/\/doi.org\/10.1007\/s00520-012-1448-1.","journal-title":"Support Care Cancer"},{"issue":"suppl 5","key":"8572_CR4","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl 5):v119\u201333. https:\/\/doi.org\/10.1093\/annonc\/mdw270.","journal-title":"Ann Oncol"},{"issue":"24","key":"8572_CR5","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020;38(24):2782\u201397. https:\/\/doi.org\/10.1200\/JCO.20.01296.","journal-title":"J Clin Oncol"},{"key":"8572_CR6","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 1. 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed 11 Apr 2021."},{"key":"8572_CR7","doi-asserted-by":"crossref","unstructured":"Aogi K, Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K, et al. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in japan: update summary of the 2015 Japan society of clinical oncology clinical practice guidelines for antiemesis. Int J Clin Oncol. 2021;26(1):1\u201317.","DOI":"10.1007\/s10147-020-01818-3"},{"issue":"9","key":"8572_CR8","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00520-009-0737-9","volume":"18","author":"PJ Hesketh","year":"2010","unstructured":"Hesketh PJ, Aapro M, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer. 2010;18(9):1171\u20137. https:\/\/doi.org\/10.1007\/s00520-009-0737-9.","journal-title":"Support Care Cancer"},{"issue":"6","key":"8572_CR9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00520-010-0899-5","volume":"19","author":"DG Warr","year":"2011","unstructured":"Warr DG, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer. 2011;19(6):807\u201313. https:\/\/doi.org\/10.1007\/s00520-010-0899-5.","journal-title":"Support Care Cancer"},{"issue":"1","key":"8572_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00520-010-1073-9","volume":"20","author":"DL Hilarius","year":"2012","unstructured":"Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer. 2012;20(1):107\u201317. https:\/\/doi.org\/10.1007\/s00520-010-1073-9.","journal-title":"Support Care Cancer"},{"issue":"6","key":"8572_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/cas.12146","volume":"104","author":"I Sekine","year":"2013","unstructured":"Sekine I, Segawa Y, Kubota K, Saeki T. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci. 2013;104(6):711\u20137. https:\/\/doi.org\/10.1111\/cas.12146.","journal-title":"Cancer Sci"},{"issue":"3","key":"8572_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.lungcan.2014.03.017","volume":"84","author":"Y Ito","year":"2014","unstructured":"Ito Y, Karayama M, Inui N, Kuroishi S, Nakano H, Nakamura Y, et al. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer. 2014;84(3):259\u201364. https:\/\/doi.org\/10.1016\/j.lungcan.2014.03.017.","journal-title":"Lung Cancer"},{"issue":"3","key":"8572_CR13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.lungcan.2015.11.009","volume":"90","author":"H Kusagaya","year":"2015","unstructured":"Kusagaya H, Inui N, Karayama M, Fujisawa T, Enomoto N, Kuroishi S, et al. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer. Lung Cancer. 2015;90(3):410\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2015.11.009.","journal-title":"Lung Cancer"},{"issue":"1","key":"8572_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00520-014-2339-4","volume":"23","author":"T Kitazaki","year":"2015","unstructured":"Kitazaki T, Fukuda Y, Fukahori S, Oyanagi K, Soda H, Nakamura Y, et al. Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy. Support Care Cancer. 2015;23(1):185\u201390. https:\/\/doi.org\/10.1007\/s00520-014-2339-4.","journal-title":"Support Care Cancer"},{"issue":"1","key":"8572_CR15","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1186\/s40064-016-3769-x","volume":"5","author":"T Miya","year":"2016","unstructured":"Miya T, Kobayashi K, Hino M, Ando M, Takeuchi S, Seike M, et al. Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy. SpringerPlus. 2016;5(1):2080. https:\/\/doi.org\/10.1186\/s40064-016-3769-x.","journal-title":"SpringerPlus"},{"issue":"4","key":"8572_CR16","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bjc.2013.400","volume":"109","author":"M Tanioka","year":"2013","unstructured":"Tanioka M, Kitao A, Matsumoto K, Shibata N, Yamaguchi S, Fujiwara K, et al. A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer. 2013;109(4):859\u201365. https:\/\/doi.org\/10.1038\/bjc.2013.400.","journal-title":"Br J Cancer"},{"issue":"3","key":"8572_CR17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10147-015-0928-y","volume":"21","author":"H Yahata","year":"2016","unstructured":"Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ohgami T, Saito T, et al. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol. 2016;21(3):491\u20137. https:\/\/doi.org\/10.1007\/s10147-015-0928-y.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"8572_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.6004\/jadpro.2014.5.1.8","volume":"5","author":"MV Brafford","year":"2014","unstructured":"Brafford MV, Glode A. Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014;5(1):24\u20139. https:\/\/doi.org\/10.6004\/jadpro.2014.5.1.8.","journal-title":"J Adv Pract Oncol"},{"issue":"5","key":"8572_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9(5):188\u201395. https:\/\/doi.org\/10.1016\/j.suponc.2011.05.002.","journal-title":"J Support Oncol"},{"issue":"1","key":"8572_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1756-9966-28-131","volume":"28","author":"L Tan","year":"2009","unstructured":"Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, et al. Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res. 2009;28(1):131. https:\/\/doi.org\/10.1186\/1756-9966-28-131.","journal-title":"J Exp Clin Cancer Res"},{"key":"8572_CR21","first-page":"3439707","volume":"2016","author":"G Babu","year":"2016","unstructured":"Babu G, Saldanha SC, Kuntegowdanahalli Chinnagiriyappa L, Jacob LA, Mallekavu SB, Dasappa L, et al. The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India. Chemother Res Pract. 2016;2016:3439707.","journal-title":"Chemother Res Pract"},{"issue":"2","key":"8572_CR22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s12013-014-0489-0","volume":"72","author":"X Wang","year":"2015","unstructured":"Wang X, Wang L, Wang H, Zhang H. Effectiveness of olanzapine combined with ondansetron in prevention of chemotherapy-induced nausea and vomiting of non-small cell lung cancer. Cell Biochem Biophys. 2015;72(2):471\u20133. https:\/\/doi.org\/10.1007\/s12013-014-0489-0.","journal-title":"Cell Biochem Biophys"},{"issue":"2","key":"8572_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375(2):134\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1515725.","journal-title":"N Engl J Med"},{"issue":"2","key":"8572_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(2):242\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(19)30678-3.","journal-title":"Lancet Oncol"},{"issue":"2","key":"8572_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","volume":"23","author":"T Yanai","year":"2018","unstructured":"Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, et al. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol. 2018;23(2):382\u20138. https:\/\/doi.org\/10.1007\/s10147-017-1200-4.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"8572_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00280-019-03868-5","volume":"84","author":"K Tanaka","year":"2019","unstructured":"Tanaka K, Inui N, Karayama M, Yasui H, Hozumi H, Suzuki Y, et al. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer Chemother Pharmacol. 2019;84(1):147\u201353. https:\/\/doi.org\/10.1007\/s00280-019-03868-5.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"8572_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.ygyno.2020.01.004","volume":"156","author":"H Iihara","year":"2020","unstructured":"Iihara H, Shimokawa M, Hayasaki Y, Fujita Y, Abe M, Takenaka M, et al. Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: a multi-institution phase II study. Gynecol Oncol. 2020;156(3):629\u201335. https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.004.","journal-title":"Gynecol Oncol"},{"key":"8572_CR28","doi-asserted-by":"publisher","unstructured":"Sakai C, Shimokawa M, Iihara H, Fujita Y, Ikemura S, Hirose C, et al. Low-dose olanzapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic malignancies: A prospective multicenter phase II trial. Oncologist. 2021;26(6):e1066-e1072. https:\/\/doi.org\/10.1002\/onco.13772.","DOI":"10.1002\/onco.13772"},{"key":"8572_CR29","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198509844.001.0001","volume-title":"The statistical evaluation of medical tests for classification and prediction","author":"MS Pepe","year":"2003","unstructured":"Pepe MS. The statistical evaluation of medical tests for classification and prediction. New York, USA: Oxford University Press; 2003."},{"issue":"1","key":"8572_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41\u201355. https:\/\/doi.org\/10.1093\/biomet\/70.1.41.","journal-title":"Biometrika."},{"issue":"2","key":"8572_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150\u201361. https:\/\/doi.org\/10.1002\/pst.433.","journal-title":"Pharm Stat"},{"issue":"19","key":"8572_CR32","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","volume":"17","author":"RB D\u2019Agostino","year":"1998","unstructured":"D\u2019Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265\u201381. https:\/\/doi.org\/10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B.","journal-title":"Stat Med"},{"issue":"4","key":"8572_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.12788\/jcso.0245","volume":"14","author":"RM Navari","year":"2016","unstructured":"Navari RM, Nagy CK, Le-Rademacher J, Loprinzi CL. Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J Community Support Oncol. 2016;14(4):141\u20137. https:\/\/doi.org\/10.12788\/jcso.0245.","journal-title":"J Community Support Oncol"},{"issue":"2","key":"8572_CR34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10147-015-0908-2","volume":"21","author":"H Iihara","year":"2016","unstructured":"Iihara H, Fujii H, Yoshimi C, Yamada M, Suzuki A, Matsuhashi N, et al. Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy. Int J Clin Oncol. 2016;21(2):409\u201318. https:\/\/doi.org\/10.1007\/s10147-015-0908-2.","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"8572_CR35","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10637-020-00903-8","volume":"38","author":"J Cao","year":"2020","unstructured":"Cao J, Ouyang Q, Wang S, Ragaz J, Wang X, Teng Y, et al. Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial. Investig New Drugs. 2020;38(2):507\u201314. https:\/\/doi.org\/10.1007\/s10637-020-00903-8.","journal-title":"Investig New Drugs"},{"issue":"3","key":"8572_CR36","doi-asserted-by":"publisher","first-page":"451","DOI":"10.22037\/ijpr.2020.113955.14584","volume":"19","author":"A Maleki","year":"2020","unstructured":"Maleki A, Ghadiyani M, Salamzadeh J, Salari S, Banihashem S, Tavakoli-Ardakani M. Comparison of mirtazapine and olanzapine on nausea and vomiting following anthracycline-cyclophosphamide chemotherapy regimen in patients with breast cancer. Iran J Pharm Res. 2020;19(3):451\u201364. https:\/\/doi.org\/10.22037\/ijpr.2020.113955.14584.","journal-title":"Iran J Pharm Res"},{"issue":"12","key":"8572_CR37","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1365-2044.2010.06561.x","volume":"65","author":"FL Chang","year":"2010","unstructured":"Chang FL, Ho ST, Sheen MJ. Efficacy of mirtazapine in preventing intrathecal morphine induced nausea and vomiting after orthopedic surgery. Anaesthesia. 2010;65(12):1206\u201311. https:\/\/doi.org\/10.1111\/j.1365-2044.2010.06561.x.","journal-title":"Anaesthesia"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08572-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08572-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08572-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T06:58:45Z","timestamp":1699253925000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08572-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8572"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08572-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,19]]},"assertion":[{"value":"28 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study 1 was approved by the Medical review board of Hamamatsu University Graduate School of Medicine (16\u2013296). Studies 2 and 3 were approved by the Medical review board of Gifu University Graduate School of Medicine (30\u2013002, 2018\u201319). These studies were conducted according to the Declaration of Helsinki and the ethical guidelines for clinical studies. Written informed consent was obtained from all patients. For this integrated study, study 1 was as an opt-out method for the secondary use of data with the approval of the Medical review board of Hamamatsu University Graduate School of Medicine (20\u2013335), and for study 2 and 3, patient written informed consent was obtained for the secondary use of data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"832"}}